Comparison of buprenorphine and methadone maintenance in opiate addicts

H Eder1, G Fischer, W Gombas

  • 1Department of General Psychiatry, University Hospital of Psychiatry, Währinger Gürtel, Vienna, Austria. drogenambulanz@akh-wien.ac.at

Insights

Buprenorphine, an opioid dependency treatment, showed promise for drug abstinence but had lower retention rates than methadone. The 8 mg buprenorphine dose may have been too low for some patients.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Research

Background:

  • Buprenorphine is a partial micro-opioid receptor agonist used for opioid dependency maintenance.
  • It offers potential advantages like lower dependence and milder withdrawal symptoms compared to full agonists.
  • Prior research suggested 8 mg sublingual buprenorphine efficacy comparable to 60 mg oral methadone.

Purpose of the Study:

  • To compare the efficacy of buprenorphine and methadone in treating opioid-dependent subjects.
  • To assess treatment retention and drug abstinence rates in patients receiving either buprenorphine or methadone.

Main Methods:

  • A 24-week European study involving 34 opioid-dependent subjects (16 buprenorphine, 18 methadone).
  • Free dosing schedule used, with a maximum buprenorphine dose of 8 mg and no upper limit for methadone.
  • Primary outcomes included drug abstinence (weekly urine analysis for opioids, cocaine, benzodiazepines) and treatment retention.

Main Results:

  • The buprenorphine group had a higher proportion of drug-negative urine samples, particularly for cocaine, though not statistically significant.
  • Treatment retention was significantly lower in the buprenorphine group compared to the methadone group.
  • The 8 mg buprenorphine dose limit may have influenced results, potentially being insufficient for highly dependent individuals.

Conclusions:

  • Buprenorphine demonstrates effectiveness in treating opioid dependency, particularly in more motivated individuals.
  • Further research is recommended to investigate buprenorphine's efficacy in specific patient subgroups.
  • The maximum 8 mg dose of buprenorphine may require adjustment for optimal outcomes in certain patient populations.

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Drug Dependence01:17

Drug Dependence

Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...